靶向尿酸可预防失血性休克大鼠模型的脑损伤和焦虑
该研究为动物实验,将雄性Wistar大鼠随机分为SHAM组、失血性休克(HS)组和HS+尿酸酶组(HS+U,尿酸酶1.5 mg/kg,于液体复苏时给药)。结果显示,HS后出现血脑屏障功能障碍(荧光素钠通透性及ICAM-1表达增加)、神经炎症(MPO活性、Iba1和GFAP表达增加)、凋亡(caspase-3活性及TUNEL增加)和神经退行性变(Fluoro-Jade),并出现焦虑样行为;尿酸酶干预可预防上述改变。结论提示尿酸是HS后循环中的新型炎症介质,靶向尿酸可能作为辅助治疗减少人类失血性休克相关脑功能障碍,但尚需临床验证。
要点
- 在大鼠失血性休克模型中,液体复苏时给予尿酸酶1.5 mg/kg可预防血脑屏障功能障碍(荧光素钠通透性及ICAM-1表达)。
- 尿酸酶干预可预防HS后神经炎症,表现为MPO活性、Iba1和GFAP表达的增加被抑制。
- 尿酸酶干预可预防HS后凋亡(caspase-3活性及TUNEL)和神经退行性变(Fluoro-Jade)。
- HS后大鼠出现焦虑样行为(强迫游泳、高架十字迷宫、社交互动测试),尿酸酶治疗可减轻该行为。
- 该研究为动物实验,靶向尿酸作为失血性休克辅助治疗减少脑功能障碍的潜力尚需人体研究验证。
适用人群与场景
- 雄性Wistar大鼠失血性休克模型;原文未提及人类适用人群、纳入或排除标准。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 在液体复苏时给予尿酸酶1.5 mg/kg(大鼠),以靶向清除循环尿酸;原文未提及给药途径、频次或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:动物实验(大鼠),样本量与中心数原文未提及;人群为雄性Wistar大鼠,随机分为SHAM组、HS组和HS+U组(尿酸酶1.5 mg/kg,液体复苏时给药)。
- 关键次要终点:HS后神经炎症(MPO活性、Iba1和GFAP表达)、凋亡(caspase-3活性、TUNEL)和神经退行性变(Fluoro-Jade)均显著增加,尿酸酶干预可预防;原文未提供具体数值与P值。
- 行为学结果:强迫游泳、高架十字迷宫和社交互动测试检测到HS后焦虑样行为,尿酸酶治疗组该行为被削弱;原文未提供具体数值与P值。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:动物实验(大鼠模型);原文未给出证据等级或推荐强度。
- 局限:原文未明确列出局限;设计本身为单中心动物实验、样本量未提及、结果需人体研究验证。
对床旁实践的改变
- 该内容提示尿酸可能是失血性休克后脑损伤的循环炎症介质,靶向尿酸或可作为辅助治疗方向,但目前仅在大鼠模型中验证,不能改变急诊/ICU现有临床实践。
- 适用与不适用人群:原文仅涉及雄性Wistar大鼠失血性休克模型;人类适用人群、不适用人群及排除标准原文未提及。
- 常见陷阱:不能将动物实验中的尿酸酶1.5 mg/kg剂量直接外推至人类;原文未提供给药途径、频次和疗程,临床决策仍需等待人体研究。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Secondary brain injury following hemorrhagic shock (HS) is a frequent complication in patients, even in the absence of direct brain trauma, leading to behavioral changes and more specifically anxiety and depression. Despite preclinical studies showing inflammation and apoptosis in the brain after HS, none have addressed the impact of circulating mediators. Our group demonstrated an increased uric acid (UA) circulation in rats following HS. Since UA is implicated in endothelial dysfunction and inflammatory response, we hypothesized UA could alter the blood-brain barrier (BBB) and impact the brain. Male Wistar rats were randomly assigned to: SHAM, HS (hemorrhagic shock) and HS + U (hemorrhagic shock + 1.5 mg/kg of uricase). The uricase intervention, specifically targeting UA, was administered during fluid resuscitation. It prevented BBB dysfunction (fluorescein sodium salt permeability and expression of intercellular adhesion molecule-1) following HS. As for neuroinflammation, all of the results obtained (MPO activity; Iba1 and GFAP expression) showed a significant increase after HS, also prevented by the uricase. The same pattern was observed after quantification of apoptosis (caspase-3 activity and TUNEL) and neurodegeneration (Fluoro-Jade). Finally, the forced swim, elevated plus maze, and social interaction tests detected anxiety-like behavior after HS, which was blunted in rats treated with the uricase. In conclusion, we have identified UA as a new circulatory inflammatory mediator, responsible for brain alterations and anxious behavior after HS in a murine model. The ability to target UA holds the potential of an adjunctive therapeutic solution to reduce brain dysfunction related to hemorrhagic shock in human.
参考来源
- L'Ecuyer S, Gilbert K, Brochu B, et al. Targeting Uric Acid Prevents Brain Injury and Anxiety in a Rat Model of Hemorrhagic Shock. Shock. 2021. PMID: 33394973. doi:10.1097/SHK.0000000000001708
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。